Overview

SCIENTIFIC SCORE
Possibly Effective
Based on 49 Researches
7.2
USERS' SCORE
Good
Based on 5 Reviews
8.5
Supplement Facts
Serving Size: 2 Soft Gels
Amount Per Serving
%DV
Calories
20
 
Total Fat
2 g
3%
Saturated Fat
0 g
0%
Trans Fat
0 g
Vitamin D3 (cholecalciferol)
25 mcg (1000 IU)
125%
Total Omega-3s♦
1280 mg
EPA (Eicosapentaenoic Acid)
650 mg
DHA (Docosahexaenoic Acid)
450 mg

Top Medical Research Studies

We examined the relationship between plasma omega-3 levels and heart failure (HF), focusing on how this affects mortality in patients with existing HF. Our analysis of the UK Biobank, which included nearly 272,000 participants without HF, showed that higher omega-3 levels were linked to a 21% lower risk of developing HF over nearly 14 years.

For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
Read More
We investigated how eicosapentaenoic acid (EPA) affects heart rhythm, particularly in the context of high-fat diets. In our study, mice were divided into two groups: one received a high-fat diet, while the other’s diet was supplemented with EPA for eight weeks.

We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
Read More
9
High-dose omega-3 improves heart function
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.

Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.

However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Read More

Most Useful Reviews

9
Normal cholesterol levels
Product quality is excellent! One of the best omega compositions, cholesterol is normal and my heart feels resilient; just ensure to take the vitamins on schedule for the best results in preventing heart disease.
Read More
9
Healthy heart function
Excellent Omega-D3 Ultimate Lemon Flavour Supplement from Nordic Naturals. Each two soft gels contain 1280 mg of omega-3 fatty acids and 1000 IU of Vitamin D3. Omega-3s support heart function, brain health, and vision. DHA promotes nerve cell health, while Vitamin D3 aids in immune support. I highly recommend this supplement for maintaining heart disease health.
Read More
7.5
Effective heart support
The first thing I noticed was the transparency regarding the quality and source of ingredients. This supplement showcases Nordic Naturals' commitment to high-grade fish oil from wild-caught fish. The addition of Vitamin D3 supports bone health and immunity, particularly as one ages. The packaging is well-designed and ensures freshness from the first to the last soft gel, safeguarding the benefits for treating heart disease.
Read More

Medical Researches

SCIENTIFIC SCORE
Possibly Effective
Based on 49 Researches
7.2
  • All Researches
We analyzed the impact of different fatty acid-derived acylcarnitines on heart health. The study found that saturated and monounsaturated acylcarnitines, especially trans-elaidoylcarnitine, significantly impaired heart function and mitochondrial activity, leading to cardiotoxicity.

In contrast, omega-3-derived acylcarnitines, like eicosapentaenoylcarnitine and docosahexaenoylcarnitine, were found to be safe, having little to no negative effect on heart function and cell viability. Overall, this research suggests that omega-3 fatty acids may be a safer option for those facing cardiac challenges.
Read More
9
High-dose omega-3 improves heart function
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.

Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.

However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Read More
We examined the relationship between plasma omega-3 levels and heart failure (HF), focusing on how this affects mortality in patients with existing HF. Our analysis of the UK Biobank, which included nearly 272,000 participants without HF, showed that higher omega-3 levels were linked to a 21% lower risk of developing HF over nearly 14 years.

For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
Read More
9
Omega-3 benefits African Americans’ heart health
We observed that the role of omega-3 fatty acids in heart health showed promising results specifically for African Americans. By comparing matched groups from the VITAL trial, we found that omega-3 supplementation significantly reduced the risk of myocardial infarction in African Americans, while no such benefit was seen in non-Hispanic whites.

This suggests that genetic or lifestyle factors may influence the effectiveness of these supplements. Our findings highlight the importance of further research to better understand how race affects responses to omega-3 supplementation.
Read More
We explored the impact of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on heart disease through a significant study known as the VITAL trial. This study involved nearly 26,000 older adults in the U.S. and aimed to determine the effects of daily EPA supplementation on cardiovascular events over an average follow-up of 5.3 years.

Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.

This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Read More

User Reviews

USERS' SCORE
Good
Based on 5 Reviews
8.5
  • All Reviews
  • Positive Reviews
  • Negative Reviews
9
Normal cholesterol levels
Product quality is excellent! One of the best omega compositions, cholesterol is normal and my heart feels resilient; just ensure to take the vitamins on schedule for the best results in preventing heart disease.
Read More
9
Healthy heart function
Excellent Omega-D3 Ultimate Lemon Flavour Supplement from Nordic Naturals. Each two soft gels contain 1280 mg of omega-3 fatty acids and 1000 IU of Vitamin D3. Omega-3s support heart function, brain health, and vision. DHA promotes nerve cell health, while Vitamin D3 aids in immune support. I highly recommend this supplement for maintaining heart disease health.
Read More
7.5
Effective heart support
The first thing I noticed was the transparency regarding the quality and source of ingredients. This supplement showcases Nordic Naturals' commitment to high-grade fish oil from wild-caught fish. The addition of Vitamin D3 supports bone health and immunity, particularly as one ages. The packaging is well-designed and ensures freshness from the first to the last soft gel, safeguarding the benefits for treating heart disease.
Read More
9
Improved heart health
I am delighted with this purchase! This product combines omega-3 fatty acids and Vitamin D3 in a good dosage, enhancing absorption. These vitamins bolster my immune system and support the heart, joints, and bones. I've noticed stronger hair and nails, plus my cholesterol levels have improved, contributing positively to treating heart disease.
Read More
7.5
Good quality assurance
The quality of this company is impressive. The ingredients include Omega 3 without a fishy taste. There are many benefits for the heart, but caution is needed with vitamin intake to avoid negative effects; regular testing is crucial in treating heart disease.
Read More

Frequently Asked Questions

9
Improved heart health
I am delighted with this purchase! This product combines omega-3 fatty acids and Vitamin D3 in a good dosage, enhancing absorption. These vitamins bolster my immune system and support the heart, joints, and bones. I've noticed stronger hair and nails, plus my cholesterol levels have improved, contributing positively to treating heart disease.
9
Normal cholesterol levels
Product quality is excellent! One of the best omega compositions, cholesterol is normal and my heart feels resilient; just ensure to take the vitamins on schedule for the best results in preventing heart disease.
9
Healthy heart function
Excellent Omega-D3 Ultimate Lemon Flavour Supplement from Nordic Naturals. Each two soft gels contain 1280 mg of omega-3 fatty acids and 1000 IU of Vitamin D3. Omega-3s support heart function, brain health, and vision. DHA promotes nerve cell health, while Vitamin D3 aids in immune support. I highly recommend this supplement for maintaining heart disease health.
7.5
Good quality assurance
The quality of this company is impressive. The ingredients include Omega 3 without a fishy taste. There are many benefits for the heart, but caution is needed with vitamin intake to avoid negative effects; regular testing is crucial in treating heart disease.
9
High-dose omega-3 improves heart function
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.

Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.

However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
We explored the impact of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on heart disease through a significant study known as the VITAL trial. This study involved nearly 26,000 older adults in the U.S. and aimed to determine the effects of daily EPA supplementation on cardiovascular events over an average follow-up of 5.3 years.

Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.

This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
4
CAC progression in diabetic patients
We explored the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on the progression of coronary artery calcium (CAC) in individuals with heart disease. In a randomized trial involving 242 subjects already on statin therapy, half received daily doses of both EPA and DHA, while the other half did not receive these supplements.

Our findings indicated a notable interaction between diabetes status and the effects of these supplements. Specifically, subjects with diabetes who took EPA and DHA experienced a greater increase in CAC scores compared to those with diabetes in the control group. This suggests that for individuals with diabetes, the use of these omega-3 fatty acids might not be beneficial, as they witnessed significant progression in heart disease markers over a 30-month period.

Meanwhile, we observed no significant difference in CAC progression between the treatment and control groups among those without diabetes. This raises questions about the complex role of EPA and DHA in heart health, particularly in the context of diabetes. Further research is needed to clarify whether this CAC progression indicates worsening disease or if it reflects a stabilization of existing plaques.
8
Omega-3 reduces heart disease risk
We explored the effectiveness of icosapent ethyl, a form of omega-3 fish oil, in lowering heart disease rates among high-risk patients with varying cholesterol levels.

In a clinical trial with statin-treated individuals who had elevated triglycerides, it was found that those taking icosapent ethyl experienced significantly fewer cardiovascular events compared to those on a placebo.

Notably, this benefit was seen regardless of their baseline low-density lipoprotein cholesterol (LDL-C) levels, indicating positive outcomes even for patients with well-controlled cholesterol.
We investigated how eicosapentaenoic acid (EPA) affects heart rhythm, particularly in the context of high-fat diets. In our study, mice were divided into two groups: one received a high-fat diet, while the other’s diet was supplemented with EPA for eight weeks.

We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.

References

  1. Liepinsh E, Gukalova B, Krims-Davis K, Kuka J, Leduskrasta A, et al. EPA and DHA acylcarnitines are less cardiotoxic than are saturated and monounsaturated long-chain acylcarnitines. Biofactors. 2025;51:e70014. doi:10.1002/biof.70014
  2. Xu J, Peng T, Kong L, Wei N. A global analysis of the burden of ischemic heart disease attributable to diet low in ω-3 fatty acids between 1990 and 2021. BMC Cardiovasc Disord. 2025;25:188. doi:10.1186/s12872-025-04620-z
  3. Horii K, Ono K, Sumi T, Higashihara M, Zaima N, et al. Eicosapentaenoic acid prevents atrial electrocardiographic impairments and atrial fibrillation in high fat diet mice. J Physiol Sci. 2025;75:100014. doi:10.1016/j.jphyss.2025.100014
  4. Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, et al. Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study. Lipids Health Dis. 2025;24:88. doi:10.1186/s12944-025-02500-1
  5. Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
  6. Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
  7. Hemmati R, Bahrami Zanjanbar D, Shishesaz MI, Soleimani A, Yari T. The impact of Omega-3 supplementation on arrhythmia reduction in acute coronary syndrome patients: a randomized clinical trial. J Complement Integr Med. 2025;22:173. doi:10.1515/jcim-2024-0427
  8. Wang Y, Wu G, Wang Y, Rehman A, Yu L, et al. Recent developments, challenges, and prospects of dietary omega-3 PUFA-fortified foods: Focusing on their effects on cardiovascular diseases. Food Chem. 2025;470:142498. doi:10.1016/j.foodchem.2024.142498
  9. Jawad MA, O'Keefe JH, Tintle N, O'Keefe EL, Franco WG, et al. Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities. Mayo Clin Proc. 2024;99:1895. doi:10.1016/j.mayocp.2024.08.007
  10. Lee YQ, Tan KH, Chong MF. Biomarkers of PUFA and cardiovascular risk factors and events in healthy Asian populations: a systematic review. Br J Nutr. 2024;132:1474. doi:10.1017/S0007114524002708
  11. Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
  12. Ryuno Y, Kobayashi JI, Fujimoto Y, Dotare T, Matsue Y, et al. Effect of an Enteral Formula Enriched With ω-3 Fatty Acids, Carnitine, and Vitamin D on Body Weight, Heart Weight, and Blood Biochemical Parameters in a Dahl Rat Heart Failure Model. J Cardiovasc Pharmacol. 2024;84:590. doi:10.1097/FJC.0000000000001637
  13. Sun S, Hara A, Johnstone L, Hallmark B, Watkins JC, et al. Optimal Pair Matching Combined with Machine Learning Predicts a Significant Reduction in Myocardial Infarction Risk in African Americans Following Omega-3 Fatty Acid Supplementation. Nutrients. 2024;16. doi:10.3390/nu16172933
  14. Ahmadi M, Askari VR, Shahri B, Mousavi Noghab SM, Jarahi L, et al. Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:881. doi:10.1007/s00210-024-03330-1
  15. Chen HC, Tai CJ, Huang JY, Kuo TA, Huang YD, et al. Associations of fish oil with cardiovascular disease events: results from the Taiwan longitudinal study in aging. BMC Public Health. 2024;24:1979. doi:10.1186/s12889-024-19512-8
  16. Yu Y, Gao M, Xu H. Ginger Extract and Omega-3 Fatty Acids Supplementation: A Promising Strategy to Improve Diabetic Cardiomyopathy. Physiol Res. 2024;73:351.
  17. Astani A, Maroofi A, Hekmatimoghaddam S, Sarebanhassanabadi M, Safari F. Sirtuin 1 mediates the pro-survival effects of vitamin D in angiotensin II-induced hypertrophy of H9c2 cardiomyoblasts. Mol Biol Rep. 2024;52:96. doi:10.1007/s11033-024-10168-6
  18. Sadeghi M, Momeni A, Mirsaeidi FS, Jamalian M, Amirpour A, et al. The Effect of Vitamin D Deficiency Treatment on Lipid Profile and C-reactive Protein in Patients with Ischemic Heart Disease: Double-blind Randomized Clinical Trial. Adv Biomed Res. 2024;13:79. doi:10.4103/abr.abr_380_23
  19. Sato AY, Cregor M, McAndrews K, Schurman CA, Schaible E, et al. Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease. JCI Insight. 2024;9. doi:10.1172/jci.insight.182664
  20. Stankiewicz B, Mieszkowski J, Kochanowicz A, Brzezińska P, Niespodziński B, et al. Effect of Single High-Dose Vitamin D Supplementation on Post-Ultra Mountain Running Heart Damage and Iron Metabolism Changes: A Double-Blind Randomized Controlled Trial. Nutrients. 2024;16. doi:10.3390/nu16152479
  21. Koroglu R, Koroglu M, Aygun H. Electrocardiographic, biochemical, and scintigraphic evidence for the cardioprotective effect of paricalcitol and vitamin D3 on doxorubicin-induced acute cardiotoxicity in rats. Bratisl Lek Listy. 2024;125:281. doi:10.4149/BLL_2024_42
  22. Hao N, Yong H, Zhang F, Liu C, Qiu Y, et al. Aortic calcification accelerates cardiac dysfunction via inducing apoptosis of cardiomyocytes. Int J Med Sci. 2024;21:306. doi:10.7150/ijms.90324
  23. Samavati I, Ranjbar A, Haddadi R. Cardioprotective effect of vitamin D3 on cisplatin-induced cardiotoxicity in male mice: role of oxidative stress. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:4761. doi:10.1007/s00210-023-02848-0
  24. Ogata S, Manson JE, Kang JH, Buring JE, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes. Nutrients. 2023;15. doi:10.3390/nu15194235
  25. Arroyo E, Leber CA, Burney HN, Li Y, Li X, et al. Epimeric vitamin D and cardiovascular structure and function in advanced CKD and after kidney transplantation. Nephrol Dial Transplant. 2024;39:264. doi:10.1093/ndt/gfad168
  26. Hasific S, Øvrehus KA, Hosbond S, Lambrechtsen J, Kumarathurai P, et al. Effects of vitamins K2 and D3 supplementation in patients with severe coronary artery calcification: a study protocol for a randomised controlled trial. BMJ Open. 2023;13:e073233. doi:10.1136/bmjopen-2023-073233
  27. Thompson B, Waterhouse M, English DR, McLeod DS, Armstrong BK, et al. Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial. BMJ. 2023;381:e075230. doi:10.1136/bmj-2023-075230
  28. Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
  29. Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. doi:10.1007/s40261-024-01417-4
  30. Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
  31. Capece U, Gugliandolo S, Morciano C, Avolio A, Splendore A, et al. Erythrocyte Membrane Fluidity and Omega-3 Fatty Acid Intake: Current Outlook and Perspectives for a Novel, Nutritionally Modifiable Cardiovascular Risk Factor. Nutrients. 2024;16. doi:10.3390/nu16244318
  32. Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. doi:10.7759/cureus.73417
  33. O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
  34. Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
  35. Amangurbanova M, Daher R, Asbeutah AA, Vemuri B, Mirza H, et al. Higher epicardial adipose tissue volume is associated with higher coronary fatty plaque volume and is regulated by waist circumference but not EPA+DHA supplementation. J Clin Lipidol. 2024;18:e773. doi:10.1016/j.jacl.2024.06.006
  36. Kumakura H, Funada R, Matsuo Y, Iwasaki T, Nakashima K, et al. Eicosapentaenoic Acid Level Predicts Long-Term Survival and Cardiovascular or Limb Event in Peripheral Arterial Disease. Ann Vasc Dis. 2024;17:135. doi:10.3400/avd.oa.23-00079
  37. Xiao Y, Chen Y, Pietzner A, Elbelt U, Fan Z, et al. Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies. Nutrients. 2024;16. doi:10.3390/nu16111610
  38. Asbeutah AA, Daher R, Malik A, Hariri E, Alfaddagh A, et al. The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial. Am J Cardiol. 2024;225:98. doi:10.1016/j.amjcard.2024.06.001
  39. Sudo Y, Morimoto T, Tsushima R, Oka A, Sogo M, et al. Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation. J Am Heart Assoc. 2024;13:e033969. doi:10.1161/JAHA.123.033969
  40. Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024;150:425. doi:10.1161/CIRCULATIONAHA.123.065520
  41. Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. doi:10.1093/eurjpc/zwae315
  42. Lv L, Guo Y, Zheng Z, Li B. Blood metabolites mediate effects of breakfast skipping on heart failure via Mendelian randomization analysis. Sci Rep. 2024;14:18957. doi:10.1038/s41598-024-69874-7
  43. Wang Y, Yang B, Wang C. The association between fatty acids and atherosclerotic diseases: A mendelian randomization study. Clin Nutr ESPEN. 2024;63:447. doi:10.1016/j.clnesp.2024.06.018
  44. Tian S, Guo T, Qian F, Qiu Z, Lu Q, et al. Fish Oil, Plasma n-3 PUFAs, and Risk of Macro- and Microvascular Complications among Individuals with Type 2 Diabetes. J Clin Endocrinol Metab. 2024. doi:10.1210/clinem/dgae482
  45. Dinu M, Sofi F, Lotti S, Colombini B, Mattioli AV, et al. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. Eur J Prev Cardiol. 2024;31:1863. doi:10.1093/eurjpc/zwae184
  46. Braun TS, Drobner T, Kipp K, Kiehntopf M, Schlattmann P, et al. Validation of Nutritional Approaches to Modulate Cardiovascular and Diabetic Risk Factors in Patients with Hypertriglyceridemia or Prediabetes-The MoKaRi II Randomized Controlled Study. Nutrients. 2024;16. doi:10.3390/nu16091261
  47. O'Keefe EL, O'Keefe JH, Tintle NL, Westra J, Albuisson L, et al. Circulating Docosahexaenoic Acid and Risk of All-Cause and Cause-Specific Mortality. Mayo Clin Proc. 2024;99:534. doi:10.1016/j.mayocp.2023.11.026
  48. Zeinalabedini M, Ladaninezhad M, Mobarakeh KA, Hoshiar-Rad A, Shekari S, et al. Association of dietary fats with ischemic heart disease (IHD): a case-control study. J Health Popul Nutr. 2024;43:19. doi:10.1186/s41043-023-00489-w
  49. Rennemo J, Berge K, Yousaf MN, Eriksen TB, Welde E, et al. An Atypical Course of Cardiomyopathy Syndrome (CMS) in Farmed Atlantic Salmon () Fed a Clinical Nutrition Diet. Microorganisms. 2023;12. doi:10.3390/microorganisms12010026
image